Back to search
Women With BRCA1 Germline Deleterious Mutation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Women With BRCA1 Germline Deleterious Mutation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Women With BRCA1 Germline Deleterious Mutation trials you may qualify forBRCA1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included. These patients will be followed up during 30 mon…
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homolo…
Background: \- The new drug BMN 673 (talazoparib) has been shown to fight tumor cells in animals and some people. It is a poly (ADP-ribose) polymerase (PARP) i…